Genetic Testing in Prostate Cancer: Clinical Implications for Early Detection and Management of Localized and Advanced Disease Webcast (2022)

There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of the breast cancer gene (BRCA1/2) mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. poly [ADP-ribose] polymerase [PARP] inhibition), urologists are now confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with localized or metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in >10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care, including pivotal clinical trial data. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer.


Support provided by independent educational grants from:

Exact Sciences
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme

Target Audience

  • Urologists
  • Residents

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.
  2. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
  3. Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results.
  4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Todd Morgan, MD

has a financial relationship (Scientific Study or Trial (Oncology)) with MDxHealth;.
has a financial relationship (Consultant or Advisor (Oncology)) with Stratify Genomics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant Biosciences;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Myriad Genetics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tempus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Blue Earth;.

Leonard Gomella, MD

has a financial relationship (Intellectual Property Interest (Oncology)) with Thomas Jefferson University;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with Wolters Kluwer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exelixis;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with MDx Health;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with McGraw Hill;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck Pharmaceuticals;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with Merck Manual;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with Canadian Journal of Urology;.


Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.



 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.


Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.


The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.


Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.


The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.